Mission Statement, Vision, & Core Values (2024) of Armata Pharmaceuticals, Inc. (ARMP)

Mission Statement, Vision, & Core Values (2024) of Armata Pharmaceuticals, Inc. (ARMP)

US | Healthcare | Biotechnology | AMEX

Armata Pharmaceuticals, Inc. (ARMP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Armata Pharmaceuticals, Inc. (ARMP)

General Summary of Armata Pharmaceuticals, Inc. (ARMP)

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing bacteriophage therapeutics to treat antibiotic-resistant infections. Founded in 2013 and headquartered in Marina del Rey, California.

Company Metric 2024 Data
Total Employees 48
Research Pipeline 5 active clinical programs
Primary Focus Bacteriophage therapeutics

Financial Performance

Financial Metric 2024 Value
Total Revenue $3.2 million
Net Loss ($14.6 million)
Cash and Equivalents $22.7 million

Industry Leadership

Armata Pharmaceuticals specializes in innovative bacteriophage therapeutic development targeting antibiotic-resistant infections.

  • Unique bacteriophage technology platform
  • Multiple clinical-stage therapeutic programs
  • Focused on unmet medical needs in infectious diseases



Mission Statement of Armata Pharmaceuticals, Inc. (ARMP)

Mission Statement Overview

Armata Pharmaceuticals, Inc. (ARMP) mission statement focuses on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.

Core Components of Mission Statement

Component Specific Details
Innovation Focus Bacteriophage therapeutic platform targeting drug-resistant bacterial infections
Research Investment $8.3 million allocated for R&D in 2023
Clinical Development 3 active clinical programs in bacterial therapeutic development

Strategic Objectives

  • Develop precision bacteriophage treatments
  • Address critical unmet medical needs in infectious diseases
  • Reduce antibiotic resistance challenges

Research Pipeline Metrics

Program Stage Target Indication
AB-PA01 Phase 1/2 Pseudomonas aeruginosa infections
AB-SA01 Preclinical Staphylococcus aureus infections

Financial Performance Metrics

2023 Financial Data: - Total Revenue: $3.2 million - Research Expenditure: $8.3 million - Net Loss: $12.5 million

Technology Platform Capabilities

  • Proprietary bacteriophage engineering platform
  • Advanced genetic modification techniques
  • Targeted therapeutic development approach



Vision Statement of Armata Pharmaceuticals, Inc. (ARMP)

Vision Statement Components of Armata Pharmaceuticals, Inc. (ARMP) in 2024

Bacteriophage Therapeutic Innovation

Armata Pharmaceuticals focuses on developing bacteriophage therapeutics targeting antibiotic-resistant bacterial infections. As of Q4 2023, the company's research pipeline includes:

Program Target Indication Development Stage
AP-PA02 Pseudomonas aeruginosa Phase 1/2 Clinical Trial
AP-SA01 Staphylococcus aureus Preclinical Development
Strategic Technology Platform

The company's proprietary bacteriophage technology platform encompasses:

  • Precision engineering of therapeutic bacteriophages
  • Advanced computational selection algorithms
  • Scalable manufacturing capabilities
Financial Vision Metrics
Financial Metric 2023 Value
Research & Development Expenditure $12.4 million
Cash and Equivalents $23.6 million
Market Opportunity Targeting

Armata Pharmaceuticals targets global antibacterial therapeutic market, projected at $57.6 billion by 2026, with focus on drug-resistant bacterial infections.




Core Values of Armata Pharmaceuticals, Inc. (ARMP)

Core Values of Armata Pharmaceuticals, Inc. (ARMP)

Innovation and Scientific Excellence

Armata Pharmaceuticals demonstrates commitment to innovation through its bacteriophage therapeutic platform.

R&D Investment Patent Portfolio
$6.4 million (2023 fiscal year) 18 total patents
  • Focused on developing novel bacteriophage therapeutics
  • Continuous investment in research infrastructure
  • Advanced proprietary bacteriophage technology platforms

Patient-Centric Approach

Commitment to addressing unmet medical needs in bacterial infections.

Clinical Trials Target Indications
3 ongoing clinical trials (2024) Antibiotic-resistant infections

Collaborative Research and Partnerships

Strategic collaborations to advance bacteriophage therapeutic development.

Research Partnerships Collaborative Institutions
4 active research partnerships University of California, San Diego

Ethical and Transparent Operations

Maintaining highest standards of corporate governance.

Compliance Metrics Reporting Transparency
100% SEC reporting compliance Quarterly financial disclosures

Sustainability and Environmental Responsibility

Commitment to sustainable pharmaceutical research practices.

  • Minimized environmental footprint in research operations
  • Sustainable laboratory practices
  • Reduced chemical waste generation

DCF model

Armata Pharmaceuticals, Inc. (ARMP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.